| Literature DB >> 29618337 |
Marcella Sabino1, Victor Adriano Okstoft Carmelo2, Gianluca Mazzoni2, Katia Cappelli1, Stefano Capomaccio1, Paolo Ajmone-Marsan3, Andrea Verini-Supplizi1, Massimo Trabalza-Marinucci4, Haja N Kadarmideen5.
Abstract
BACKGROUND: Essential oil (EO) dietary supplementation is a new strategy to improve animal health. EO compounds have antiparasitic, antimicrobial, antiviral, antimycotic, antioxidant and anti-inflammatory proprieties. Nutrigenomics investigations represent innovative approaches in understanding the relation between diet effect and gene expression related to the animal performance. Few nutrigenomics studies have used a high-throughput RNA-Sequencing (RNA-Seq) approach, despite great potential of RNA-Seq data in gene expression quantification and in co-expression network analyses. Our aim is to use the potential of RNA-Sequencing data in order to evaluate the effect of an EO supplementary diet on gene expression in both lamb liver and muscle.Entities:
Keywords: Essential oils; Lamb; Liver; Muscle; RNA-Seq; WGCNA
Mesh:
Substances:
Year: 2018 PMID: 29618337 PMCID: PMC5885410 DOI: 10.1186/s12864-018-4632-y
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 2Experimental design and data analysis workflow
Interaction genes and DE genes in male in liver tissue (p-adj < 0.05)
| Symbol | Gene description | L2FC | p-adj | |
|---|---|---|---|---|
|
| calmodulin | -0,97 | 1,28E-02 | Interaction |
|
| DnaJ heat shock protein family (Hsp40) member B9 | − 1,83 | 1,66E-03 | Interaction |
|
| fibrinogen beta chain | −1,4 | 3,80E-03 | Interaction |
|
| fibrinogen gamma chain | −1,28 | 1,66E-03 | Interaction |
|
| E3 ubiquitin-protein ligase | 0,83 | 4,96E-03 | Interaction |
|
| haptoglobin | −1,54 | 4,03E-02 | Interaction |
|
| heat shock protein 90 beta family member 1 | −1,43 | 1,28E-02 | Interaction |
|
| KDEL endoplasmic reticulum protein retention receptor 2 | -1,06 | 1,28E-02 | Interaction |
|
| mesencephalic astrocyte derived neurotrophic factor | −2,23 | 3,71E-02 | Interaction |
|
| mitochondrial ribosomal protein S18B | −1,22 | 4,96E-03 | Interaction |
|
| nucleolar protein interacting with the FHA domain of MKI67 | −1,29 | 3,71E-02 | Interaction |
|
| transmembrane protein 45A | −3,09 | 1,66E-03 | Interaction |
|
| ubiquitin fold modifier 1 | −1,66 | 4,54E − 03 | Interaction |
|
| arginase 1 | −0,74 | 4,85E-03 | Male |
|
| calmodulin | -0,64 | 3,98E-02 | Male |
|
| DnaJ heat shock protein family (Hsp40) member B9 | −1,2 | 4,45E − 03 | Male |
|
| fibrinogen beta chain | −0,97 | 4,45E − 03 | Male |
|
| fibrinogen gamma chain | −0,91 | 4,21E − 03 | Male |
|
| heat shock protein 90 beta family member 1 | −0,99 | 1,57E − 02 | Male |
|
| KDEL endoplasmic reticulum protein retention receptor 2 | -0,74 | 1,58E-02 | Male |
|
| mitochondrial ribosomal protein S18B | -0,81 | 1,63E-02 | Male |
|
| nucleolar protein interacting with the FHA domain of MKI67 | -0,91 | 4,04E-02 | Male |
|
| proteasome subunit alpha 4 | -0,62 | 4,04E-02 | Male |
|
| signal peptidase complex subunit 3 | −1,24 | 4,45E − 03 | Male |
|
| Sjogren syndrome antigen B | −0,75 | 1,01E-02 | Male |
|
| transmembrane p24 trafficking protein 7 | -0,75 | 4,29E-02 | Male |
|
| ubiquitin fold modifier 1 | −1,17 | 4,45E-03 | Male |
|
| cytochrome P450 2D14 | 1,39 | 3,27E-02 | Male |
L2FC log2 fold change, p-adj p value adjusted (BH correction)
Interaction genes and DE genes in female in muscle tissue (p-adj < 0.05)
| Symbol | Gene description | L2FC | p-adj | |
|---|---|---|---|---|
|
| myosin light chain kinase family member 4 | −2,27 | 4,53E-02 | Interaction |
|
| novel Mt. tRNA | −3,16 | 2,65E-03 | Interaction |
|
| STAM binding protein like 1 | 1,47 | 4,53E-02 | Interaction |
|
| interferon-induced very large GTPase 1-like | −1,56 | 2,14E-03 | Interaction |
| – | novel Mt. tRNA | 2,54 | 9,13E-05 | Female |
L2FC log2 fold change, p-adj p value adjusted (BH correction)
Statistically significant GSEA summary results in liver of males and females (FDR < 0.05)
| KEGG pathway | Size | ES | NES | FDR | |
|---|---|---|---|---|---|
| Males | Protein Export | 15 | −0.60 | 0.000 | 0.001 |
| Proteasome | 33 | −0.37 | 0.000 | 0.002 | |
| Antigen Processing and Presentation | 20 | −0.43 | 0.000 | 0.006 | |
| Rna Degradation | 16 | −0.38 | 0.012 | 0.116 | |
| Aminoacyl Trna Biosynthesis | 19 | −0.30 | 0.031 | 0.310 | |
| Ppar Signaling Pathway | 29 | 0.43 | 0.000 | 0.000 | |
| Glycolysis Gluconeogenesis | 21 | 0.48 | 0.000 | 0.001 | |
| Drug Metabolism Cytochrome P450 | 20 | 0.44 | 0.000 | 0.006 | |
| Glycine Serine and Threonine Metabolism | 22 | 0.38 | 0.002 | 0.034 | |
| Peroxisome | 48 | 0.26 | 0.000 | 0.028 | |
| Retinol Metabolism | 16 | 0.43 | 0.006 | 0.031 | |
| Citrate Cycle Tca Cycle | 20 | 0.37 | 0.002 | 0.037 | |
| Metabolism Of Xenobiotics By Cytochrome P450 | 17 | 0.41 | 0.006 | 0.033 | |
| Females | Cytokine Cytokine Receptor Interaction | 94 | −0.21 | 0.000 | 0.019 |
| Pathogenic | 35 | 0.40 | 0.000 | 0.001 | |
| Proteasome | 34 | 0.37 | 0.000 | 0.003 | |
| Amino Sugar and Nucleotide Sugar Metabolism | 36 | 0.33 | 0.000 | 0.009 | |
| Glycolysis Gluconeogenesis | 33 | 0.34 | 0.000 | 0.017 | |
| Ecm Receptor Interaction | 55 | 0.25 | 0.000 | 0.022 | |
| Cysteine and Methionine Metabolism | 25 | 0.35 | 0.004 | 0.037 | |
| Protein Export | 19 | 0.39 | 0.002 | 0.047 |
Size = Number of genes. ES Enrichment score. ES represents the overepresentation degree of top and bottom genes included in ranked list based on log2FoldChange of DE genes included. NES Normalized enrichment score
Statistically significant GSEA summary results in muscle of males and females (FDR < 0.05)
| KEGG pathway | Size | ES | NES | FDR | |
|---|---|---|---|---|---|
| Males | Proteasome | 34 | −0.47 | −3.14 | 0.000 |
| Ecm Receptor Interaction | 58 | −0.35 | −3.11 | 0.000 | |
| Complement and Coagulation Cascades | 30 | −0.41 | −2.72 | 0.001 | |
| Spliceosome | 95 | −0.21 | −2.32 | 0.012 | |
| Ribosome | 36 | −0.32 | −2.31 | 0.009 | |
| Pyrimidine Metabolism | 62 | −0.24 | −2.20 | 0.016 | |
| Antigen Processing and Presentation | 32 | −0.32 | −2.15 | 0.020 | |
| Ppar Signaling Pathway | 44 | −0.26 | −2.06 | 0.031 | |
| Rna Degradation | 48 | −0.25 | −2.03 | 0.034 | |
| Peroxisome | 60 | −0.21 | −1.96 | 0.046 | |
| Hematopoietic Cell Lineage | 40 | −0.27 | −1.96 | 0.043 | |
| Ubiquitin Mediated Proteolysis | 102 | 0.21 | 2.46 | 0.012 | |
| Basal Cell Carcinoma | 29 | 0.37 | 2.39 | 0.012 | |
| Notch Signaling Pathway | 37 | 0.33 | 2.33 | 0.015 | |
| Mapk Signaling Pathway | 177 | 0.15 | 2.31 | 0.013 | |
| Wnt Signaling Pathway | 96 | 0.19 | 2.18 | 0.025 | |
| Females | Peroxisome | 60 | −0.30 | −2.77 | 0.000 |
| Fatty Acid Metabolism | 28 | −0.41 | −2.62 | 0.001 | |
| Spliceosome | 95 | −0.23 | −2.61 | 0.002 | |
| Butanoate Metabolism | 20 | −0.47 | −2.53 | 0.002 | |
| Proteasome | 34 | −0.36 | −2.52 | 0.002 | |
| Pyrimidine Metabolism | 62 | −0.24 | −2.23 | 0.011 | |
| Ribosome | 36 | −0.29 | −2.09 | 0.025 | |
| Propanoate Metabolism | 23 | −0.36 | −2.00 | 0.038 | |
| Valine Leucine and Isoleucine Degradation | 35 | −0.28 | −1.96 | 0.043 | |
| Nucleotide Excision Repair | 37 | −0.27 | −1.93 | 0.045 | |
| Lysine Degradation | 33 | −0.28 | −1.93 | 0.042 | |
| Tryptophan Metabolism | 21 | −0.34 | −1.91 | 0.043 | |
| Ecm Receptor Interaction | 58 | 0.45 | 4.03 | 0.000 | |
| Complement and Coagulation Cascades | 30 | 0.56 | 3.67 | 0.000 | |
| Focal Adhesion | 159 | 0.20 | 2.89 | 0.000 | |
| Hematopoietic Cell Lineage | 40 | 0.37 | 2.77 | 0.000 | |
| Regulation Of Actin Cytoskeleton | 148 | 0.19 | 2.71 | 0.000 | |
| Lysosome | 93 | 0.23 | 2.64 | 0.000 | |
| Pathogenic Escherichia Coli Infection | 35 | 0.34 | 2.44 | 0.003 | |
| Cell Adhesion Molecules Cams | 57 | 0.26 | 2.31 | 0.006 | |
| Endocytosis | 128 | 0.17 | 2.30 | 0.006 | |
| Sphingolipid Metabolism | 23 | 0.38 | 2.21 | 0.011 | |
| Cytokine Cytokine Receptor Interaction | 88 | 0.20 | 2.16 | 0.015 | |
| Pentose Phosphate Pathway | 19 | 0.40 | 2.04 | 0.030 | |
| Leukocyte Transendothelial Migration | 74 | 0.19 | 1.93 | 0.051 | |
| Glycolysis Gluconeogenesis | 32 | 0.28 | 1.93 | 0.048 |
Size = Number of genes; ES Enrichment score. ES represents the overepresentation degree of top and bottom genes included in ranked list based on log2FoldChange of DE genes included; NES Normalized enrichment score
Fig. 1Overlap between female set-specific MMs and male set-specific MMs in liver. The overlap between all modules identified in males and in females is represented in the table. Each row in the table corresponding to one male set-specific module and the column corresponds to one female set-specific module. The modules with the same number did not represent the same type of co-expressed genes included (Male_Module1 ≠ Female_Module1). The number in the table indicates the genes counted in the intersection between each module identified in both sexes. Colouring of the table indicates significant overlap evaluated using Fisher’s exact test. The intensity of the colour is proportional to the Fisher’s exact test p-value for the overlap of the two modules. The stronger red colour represents the more significant overlap